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a  b  s  t r  a  c  t
The  use of  vaccinia  virus  (VACV)  as the  vaccine  against  variola  virus  resulted  in  the eradication  of small-
pox.  VACV  has  since  been  used  in  the development  of recombinant  vaccine  and  therapeutic  vectors,  but
complications  associated  with  uncontrolled  viral  replication  have  constrained  its  use  as  a  live viral  vector.
We propose  to improve  the  safety  of  VACV  as  a  live-replicating  vector  by  using  elements  of  the tet operon
to  control  the  transcription  of  genes  that are essential  for viral  growth.  Poxviruses  encode  all  enzymes
and  factors  necessary  for their  replication  within  the  host  cell  cytoplasm.  One  essential  VACV  factor  is
the  vaccinia  early  transcription  factor  (VETF)  packaged  into  the  viral  core.  This heterodimeric  protein  is
required  for  expression  of  early  VACV  genes.  VETF  is  composed  of  a large  subunit  encoded  by the  A7L  gene
and a  small  subunit  encoded  by  the  D6R  gene.  Two  recombinant  VACVs  were  generated  in which  either
the  A7L or  D6R  gene  was  placed  under  the  control  of tet operon  elements  to  allow  their  transcription,  and
therefore  viral  replication,  to be  dependent  on  tetracycline  antibiotics  such  as  doxycycline.  In the  absencentibiotics
accinia early transcription factor
of  inducers,  no plaques  were  produced  but abortively  infected  cells  could  be  identiﬁed  by expression  of a
reporter  gene.  In  the  presence  of  doxycycline,  both  recombinant  viruses  replicated  indistinguishably  from
the wild-type  strain.  This  stringent  control  of  VACV  replication  can  be used  for the  development  of  safer,
next-generation  VACV  vaccines  and  therapeutic  vectors.  Such  replication-inducible  VACVs  would  only
replicate  when  administered  with  tetracycline  antibiotics,  and  if adverse  events  were  to occur,  treatment
would  be as  simple  as  antibiotic  cessation.
 2013©
. Introduction
Vaccinia virus (VACV) is the prototype member of the genus
rthopoxvirus within the family Poxviridae.  This genus also includes
owpox virus, monkeypox virus, and most notably variola virus,
he causative agent of smallpox. Immunization of humans with
ACV was used to successfully eradicate naturally occurring small-
ox worldwide (Wehrle, 1980). Since then, VACV has been utilized
Abbreviations: VACV, vaccinia virus; VETF, vaccinia early transcription factor;
ET, tetracycline; DOX, doxycycline; ATC, anhydrotetracycline; DPI, days post-
nfection.
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as a viral vector for the development of recombinant vaccines
for humans and animals, as well as cancer immunotherapies and
oncolytic therapies. In addition, there is still signiﬁcant interest
in the development of next-generation smallpox vaccines to be
used in case of a bioterrorist event or the emergence of other
orthopoxvirus threats. However, the safety of live VACV vectors
is always a concern, as uncontrolled replication can result in com-
plications from vaccination or therapeutic use. Although VACV has
not been associated with any disease, it can cause mild to severe
complications that include accidental infection, generalized vac-
cinia, eczema vaccinatum, progressive vaccinia, and post-vaccinial
encephalitis (Casey et al., 2005; Fenner et al., 1988; Fulginiti et al.,
2003; Henderson et al., 1999; Lane and Goldstein, 2003a). The
occurrence of complications has been correlated with pre-existing
conditions such as atopic dermatitis, cardiac disease, and immuno-
suppression due to infection (e.g., HIV/AIDS) or drug therapy.
Consequently, individuals with such conditions or with contacts
that have these conditions are contraindicated for vaccination or
Open access under CC BY-NC-ND license.treatment with replication-competent VACVs (Kemper et al., 2002;
Lane and Goldstein, 2003b).
A number of strategies have been attempted to enhance the
safety of VACV vectors, including the selection of natural strains
 license.
4  Resea
o
B
u
a
e
k
a
e
(
L
i
v
w
i
c
a
i
e
a
V
l
i
V
t
c
a
o
a
(
s
t
f
o
g
m
2
2
t
a
H
i
n
2
I
i
e
V
c
t
t
D
2
s
t
f
c
t
t
i
a
p
e
b
g4 C.J. Hagen et al. / Virus
f lower virulence such as those derived from the New York City
oard of Health (NYCBH) strain, the development of highly atten-
ated strains such as modiﬁed vaccinia Ankara (MVA), NYVAC,
nd LC16m8 (Drexler et al., 1998; Kenner et al., 2006; Tartaglia
t al., 1992), inactivation of virulence factors such as the thymidine
inase gene (Buller et al., 1985), deletion of immunomodulatory
nd other non-essential viral genes (Legrand et al., 2004; Verardi
t al., 2001), and expression of attenuating genes such as cytokines
Flexner et al., 1987; Giavedoni et al., 1992; Grigg et al., 2013;
egrand et al., 2005; Ramshaw et al., 1987). However, these safety
mprovements can lead to a reduction in the effectiveness of the
ectors. For example, vaccine efﬁcacy is typically compromised
ith attenuation, next-generation smallpox vaccines must provide
mmunogenicity in clinical trials equivalent to current licensed vac-
ines such as ACAM2000 (a clone derived from NYCBH) (Greenberg
nd Kennedy, 2008), the effectiveness of oncolytic VACV vectors
s contingent upon the replication-competence of the vector, and
xpression of cytokines can lead to unforeseen immune activation
nd complications (Bakacs et al., 2012; Tisoncik et al., 2012).
Here we propose an approach to generate replication-inducible
ACV vectors that are signiﬁcantly safer, yet replicate to the same
evels as their parental strains, and therefore maintain their full
mmunogenic and oncolytic potential. These replication-inducible
ACV vectors, based on elements of the transposon Tn10 operon
hat confers tetracycline (TET) resistance in bacteria, would repli-
ate only in the presence of tetracyclines. Tetracyclines such as TET
nd doxycycline (DOX) are commonly used broad-spectrum antibi-
tics that inhibit translation in gram-positive, gram-negative, and
typical bacteria by binding to the 30S bacterial ribosome subunit
Chopra and Roberts, 2001). In the tet operon, the Tet repres-
or (TetR) is unable to bind to tet operators in the presence of
etracyclines, allowing transcription of the efﬂux gene that con-
ers resistance to tetracyclines (Hillen and Berens, 1994). The tet
peron has been adapted to a variety of organisms for inducible
ene expression, including prokaryotes, yeast, insect, plant, and
ammalian cells, and transgenic organisms (Bertram and Hillen,
008; Faryar and Gatz, 1992; Gatz and Quail, 1988; Stebbins et al.,
001; Stieger et al., 2009; Yao et al., 1998; Zhu et al., 2002). The
et system has also been adapted to control gene expression in
 number of viruses (Cunningham et al., 2010; Gall et al., 2007;
edengren-Olcott and Hruby, 2004; Yamaguchi et al., 2012), and
n some instances for conditional replication of herpesviruses, ade-
oviruses, and retroviruses (Legrand et al., 2012; Manoussaka et al.,
013; Yao and Eriksson, 1999; Yao et al., 2010; Zhang et al., 2009).
n particular, inducible VACVs have been generated by express-
ng the TetR gene (tetR) constitutively and inserting a tet operator
lement (O2) immediately after the transcriptional start sites of
ACV genes, enabling their expression to be regulated by tetracy-
lines (Traktman et al., 2000; Unger and Traktman, 2004). Using
his system, inducible genes are expressed at minimal levels in
he absence of inducer and at high levels in the presence of TET or
OX, without any apparent effect on VACV replication (Grigg et al.,
013; Traktman et al., 2000). Therefore, we propose to improve the
afety of VACV as a live-replicating vector by using elements of the
et operon to control the transcription of genes that are essential
or viral growth. These replication-inducible VACVs would repli-
ate to wild-type levels in the presence of low concentrations of
etracyclines and would be unable to replicate in the absence of
hese antibiotics, thus allowing treatment of adverse events result-
ng from uncontrolled replication of the virus to be as simple as
ntibiotic cessation.
The vaccinia early transcription factor (VETF) is a heterodimeric
rotein required for the expression of early VACV genes (Broyles
t al., 1988). VETF is composed of an 82 kDa large subunit encoded
y the A7L gene and a 70 kDa small subunit encoded by the D6R
ene (Broyles and Fesler, 1990; Gershon and Moss, 1990). The VACVrch 181 (2014) 43–52
A7L gene is referred to as A8L in some literature; currently the A8
open reading frame is considered to be A8R and to encode a subunit
of an intermediate transcription factor (Sanz and Moss, 1999). The
VETF subunits are produced late in infection and packaged into viri-
ons to be used in the next round of replication. VETF provides early
promoter speciﬁcity by binding to early promoters and recruiting
the RNA polymerase (Baldick et al., 1994; Li and Broyles, 1993b).
A7 interacts with the core region of the early promoter while D6
interacts with the region downstream from the transcriptional start
site (Cassetti and Moss, 1996). D6 also contains the DNA-dependent
ATPase activity of the transcription factor (Li and Broyles, 1993a).
Both D6R and A7L genes have been shown to be essential for VACV
replication (Hu et al., 1996, 1998; Li et al., 1994; Yang and Moss,
2009). Thus, we used elements of the tet operon to design and
construct VACVs that inducibly express the D6R or A7L genes. We
evaluated and characterized the growth properties of these VACVs
and showed that these viruses fail to replicate in the absence of
tetracyclines, but replicate indistinguishably from wild-type VACV
in the presence of tetracycline antibiotics.
2. Materials and methods
2.1. Cells and viruses
Cell lines were obtained from the American Type Culture Collec-
tion (ATCC, Rockville, MD). African green monkey BS-C-1 (CCL-26)
and human HeLa-S3 (CCL-2.2) cells were grown in Dulbecco’s mod-
iﬁed Eagle medium (D-MEM; Life Technologies, Gaithersburg, MD)
supplemented with 10% tetracycline-tested fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA). All cells were grown at
37 ◦C in 5% CO2. The L-variant of VACV strain Western Reserve (WR)
was obtained from ATCC (VR-2035) and a clone (9.2.4.8) derived by
sequential plaque puriﬁcation was used to generate the recombi-
nant viruses in this study. High-titer stocks of VACV were obtained
in HeLa-S3 cells and titered in BS-C-1 cells.
2.2. Construction of the VACV transfer vectors
The schematic representation of the VACV transfer vector back-
bone used for the generation of the recombinant VACVs is shown in
Fig. 1C and D. The two  transfer vectors were generated in multiple
steps by a combination of DNA synthesis (DNA2.0, Menlo Park, CA),
PCR cloning, and standard subcloning, using engineered restriction
endonuclease sites (not shown) to facilitate construction. The
gpt-EGFP fusion gene for combined xanthine–guanine phosphori-
bosyl transferase (gpt) selection and enhanced green ﬂuorescent
protein (EGFP) screening was  developed by DNA synthesis of the
Escherichia coli gpt gene (based on the sequence in plasmid pMSG,
GenBank: U13860) and the EGFP gene (based on the sequence in
plasmid pEGFP-1, GenBank: U55761), using a previously developed
strategy (Cao and Upton, 1997). The tetR gene (based on GenBank:
X00694) was synthesized with an internal VACV early transcrip-
tional termination sequence (TTTTTNT) removed from the middle
of the gene (Leu codon at position 358 changed from TTA to CTT)
to ensure early gene expression. The tetR and gpt-EGFP genes were
placed under back-to-back PE/L synthetic promoters (sequence
TATTTATATTCCAAAAAAAAAAAATAAAATTTCAATTTTTAACT-
GCAGTTAAAAATTGAAATTTTATTTTTTTTTTTTGGAATATAAATA)
(Chakrabarti et al., 1997). The transfer vectors also contained
the putative D6R promoter region or a modiﬁed P11 late VACV
promoter with a tet operator (O2) (Hillen and Berens, 1994)
placed immediately after the late transcriptional initiator element
sequences, as shown in Table 1. Each cassette was  surrounded
by 600 bp of VACV genomic sequences to the left and to the
right of the insertion points shown in Fig. 1B (based on GenBank:
NC 006998) to direct homologous recombination and insertion
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Fig. 1. Schematic representation of the genomic organization of the VACVs inducibly expressing D6R (viD6R) or A7L (viA7L). (A) Genome of the WR strain of VACV showing
HindIII  restriction fragments A through P. (B) Schematic detail of the D6R, A7L, and adjacent genes within the HindIII D and A fragments of VACV WR.  (C and D) Cassettes
containing the D6R promoter (PD6R) or the F17R (P11) promoter followed by the tet operator (O2) were inserted upstream of the D6R or A7L genes to generate the recombinant
VACVs  viD6R (C) or viA7L (D). The cassettes also contain the tetR gene and the gpt-EGFP fusion gene under back-to-back synthetic early/late VACV promoters (PE/L). Expression
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if  TetR allows transcription from the tet operator-controlled promoters only in the
election of recombinant VACVs in the presence of mycophenolic acid and screenin
sed  to amplify speciﬁc genomic regions for characterization of the viruses. ITR, inv
f the cassettes within the appropriate genomic locations. All
lasmids were sequenced after synthesis or PCR cloning to conﬁrm
equence identity.
.3. Generation of VACVs and preparation of high-titer stocks
Recombinant VACVs were generated by standard homolo-
ous recombination after transfection of the transfer vectors with
uGENE HD transfection reagent (Promega, Madison, WI)  into BS-
-1 cell monolayers infected 2 h previously with VACV WR clone
.2.4.8. at a multiplicity of infection (MOI) of 0.05. Recombinant
pt-positive VACVs were plaque puriﬁed from transfection lysates
n BS-C-1 cells using selection medium (25 g/ml mycophenolic
cid, 250 g/ml xanthine, and 15 g/ml hypoxanthine) (Falkner
nd Moss, 1988) in the presence of DOX (1 g/ml). Green ﬂuores-
ent plaques were visualized under a Carl Zeiss Axio Observer D1
nverted ﬂuorescence microscope (Oberkochen, Germany) using an
F100-2 (EGFP) ﬁlter (Omega Optical, Brattleboro, VT). All VACVs
ere plaque puriﬁed at least four times to eliminate contamination
ith the parental virus. High-titer stocks were generated by infect-
ng HeLa S3 cells with the VACVs at an MOI  of 0.1 in the presence of
Table 1
Sequence of the natural D6R and A7L promoters and the t
the  inducible VACVs.
Promotera Sequ enceb
D6R natural ATATATGCTCATATATTT ATAGAAGA TATC
PD6RO2 ATATATGCTCATATATTT ATAGAAGA TATC
A7L natural TGTAAGACTTACATCATCGGTAGTAGATTT
P11 O2 ATATAGTAGAATT TCATTTT GTT TTTTTCTA
a The putative natural promoters are deﬁned as the int
genes. The O2-controlled promoters are based on the na
b The promoter sequences are shown with the putative
boxed, the start codons bolded, and the O2 operator seqence of tetracyclines. Expression of the gpt-EGFP fusion gene allows simultaneous
reen ﬂuorescent cells or plaques. Arrows with numbers indicate primers (Table 2)
 terminal repeat. Panels B–D are not drawn to scale.
DOX (1 g/ml). Infected cells were harvested 4 days post-infection
(DPI) by centrifugation at 300 × g for 10 min  and resuspension in
D-MEM without tetracyclines. Cells were then lysed by freezing
and thawing, sonicated, and trypsinized. Finally, cell lysates were
clariﬁed to remove contaminating cell debris by a second round of
sonication and centrifugation at 500 × g for 10 min.
2.4. Analysis of recombinant VACV stability and purity
To detect any residual parental VACV after plaque puriﬁcation,
the expression of the EGFP gene was conﬁrmed by ﬂuorescence
microscopy. Brieﬂy, plaque assays were performed on BS-C-1
cell monolayers in 6-well plates in the absence or presence of
DOX (1 g/ml) using high-titer stocks. After 2 days of incubation
at 37 ◦C, plaques were analyzed by both brightﬁeld and ﬂuo-
rescence microscopy to detect any EGFP-negative plaques that
could be present and would represent unstable recombinants or
recombinants needing further plaque puriﬁcation. The genomic
organization of each recombinant VACV around the insertion site
was checked by PCR analysis of viral DNA puriﬁed using a small-
scale method employing micrococcal nuclease (Lai and Chu, 1991).
et operator-controlled promoters used to generate
ACATATCTAAATG
ACATATCTAAATA TCCCTATCAG TGATAGAG ACGGCCGATG
TCACTTTACCCCACGATATAAATATG
TGCTA TAAATA TCC CTATCAG TGATAGAG ACGGCCGATG
ergenic regions upstream from the D6R and A7L
tural D6R promoter or the F17R (P11) promoter.
 late transcriptional initiator element sequences
uences underlined.
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Table 2
Primers used to amplify wild-type and recombinant VACV genomic regions.
Primer Gene Sequence (5′–3′)a
1 D5R CCTACACCCGAAGAGATTCC
2  D6R AAGCTACCAAGGCGAACAAC
3  A7L ATTGAGTCATTCGAAGCGTC
4  A8R TGGTATCCGAGTTTTTCTTG
5  tetR GACGCCTTAGCCATTGAGAT
6  EGFP ACAACCACTACCTGAGCACC
7  I8R (forward) ATTTTCCAATTCCGTAGGTAAACGA
8  I8R (reverse) TGATCATGCTCATGAACTTCGTCTA
9  D6R (forward) ATCTAACGGCCGATGAATACCGGAAT
10  D6R (reverse) TCAGTTGCTAGCTTATGGAGAAGATA
11  A7L (forward) ATAAATCGGCCGATGCGATATATAGT
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d12  A7L (reverse) AGTTGTGCTAGCTTAATTTATTTGTG
a Engineered restriction endonuclease sites are underlined.
he primer sequences used are shown in Table 2 and their relative
ocations in Fig. 1B–D. The primer combinations used for PCR anal-
sis included 1–2, 1–5, and 2–6 for the D6R recombinant VACV, as
ell as 3–4, 3–6, and 4–5 for the A7L recombinant VACV. As a pos-
tive control for VACV DNA, primers 7 and 8 were used to amplify
 region of the I8R gene (VACWR077).
.5. The effect of DOX on plaque formation
The ability of the VACVs to replicate in the absence or pres-
nce of inducer (DOX) was investigated by standard plaque assay.
rieﬂy, near-conﬂuent BS-C-1 cell monolayers in 12-well plates
ere infected with the VACVs at approximately 40 plaque-forming
nits (PFU)/well in the absence or presence of 1 g/ml DOX and
ncubated at 37 ◦C for 2, 7, or 14 days. Cells were stained and ﬁxed
n 0.5% crystal violet/20% ethanol and isolated viral plaques were
maged with a digital camera or an inverted microscope.
For the analysis of plaque formation by ﬂuorescence
icroscopy, near-conﬂuent BS-C-1 cell monolayers in six-well
lates were infected with the VACVs at 50 PFU/well in the absence
r presence of 1 g/ml DOX. Plaques and infected cells were
maged at 2, 4, 6, 8, 10, and 12 DPI. In a subset of wells infected
ith the VACVs in the absence of inducers, DOX was added at 2, 4,
, 8, or 10 DPI and any plaques that formed were imaged 2 days
ater.
.6. Transient complementation assays
Plasmids expressing the D6R or A7L genes under the VACV P11
ate promoter (pP11-D6R and pP11-A7L, respectively) were gen-
rated by PCR cloning with primers 9–10 (D6R gene) or 11–12
A7L gene) (Table 2). Forward primers included an EagI engineered
estriction endonuclease sequence preceding the start codon and
everse primers included an NheI sequence after the stop codon to
llow directional cloning into a synthetic plasmid designed to con-
ain only the P11 promoter sequence (DNA2.0). The identity of the
loned fragments was conﬁrmed by restriction enzyme analysis.
Near conﬂuent BS-C-1 cell monolayers in 24-well plates were
nfected with viD6R or viA7L at 100 PFU/well for 1 h in the absence
f tetracyclines and transfected (FuGENE HD) with 0.5 g of plas-
id  pP11-D6R or pP11-A7L. Cells were incubated at 37 ◦C and plaque
ormation was checked 2 DPI by brightﬁeld and ﬂuorescence imag-
ng. Additionally, triplicate BS-C-1 cell monolayers in 24-well plates
ere infected with viD6R or viA7L at an MOI  of 0.01 for 1 h in the
bsence of DOX and then transfected (FuGENE HD) with 0.5 g
f plasmid pP11-D6R or pP11-A7L. Cells were collected immedi-
tely (to determine input virus) or incubated at 37 ◦C for 48 h
n the absence or presence of 100 ng/ml of DOX. Brieﬂy, super-
atants were collected, centrifuged (to pellet detached cells), and
iscarded. Cells in each well were resuspended in 0.5 ml  of D-MEM,rch 181 (2014) 43–52
scraped, and added to the pellet of detached cells, containing mostly
intracellular mature virions (IMV). Virus yield was determined by
plaque assay on BS-C-1 cells in the presence of 1 g/ml of DOX, in
duplicate.
2.7. Effect of tetracyclines on plaque size
The size of the plaques formed by the VACVs in the absence
or presence of different tetracyclines was  investigated by plaque
assay. Brieﬂy, near-conﬂuent BS-C-1 cell monolayers in 12-well
plates were infected with the VACVs at 30 PFU/well in the absence
or presence of 0.1, 1, 10, 100, or 1000 ng/ml DOX, TET, or anhy-
drotetracycline (ATC) and incubated at 37 ◦C for 36 h. Cells were
stained and ﬁxed in 0.5% crystal violet/20% ethanol and the radius
of isolated plaques was measured under an inverted microscope
with measurement-capable software (AxioVision 4.8.1, Carl Zeiss).
2.8. Effect of DOX on viral growth kinetics
Viral growth kinetics in the absence or presence of DOX were
determined by generating growth curves at a low MOI. Brieﬂy, trip-
licate monolayers of near-conﬂuent BS-C-1 cells (seeded in the
absence or presence of 1 g/ml of DOX) were infected with the
VACVs at an MOI  of 0.01 for 1 h in 12-well plates. Virus replica-
tion was  determined as previously described (Verardi et al., 2001)
in the presence or absence of DOX (1 g/ml). For each time point,
virus yield was determined by plaque assay on BS-C-1 cells in the
presence of 1 g/ml of DOX, in duplicate.
2.9. Statistical analyses and image processing
Statistical analyses were performed with GraphPad Prism v. 6.0c
(GraphPad Software, La Jolla, CA). Images were processed in Adobe
Photoshop CS6 (Adobe Systems, San Jose, CA) with no manipula-
tions other than for contrast.
3. Results
3.1. Design of tet-responsive late promoters
Replication-inducible recombinant VACVs were designed by
expressing the tetR gene under a constitutive VACV promoter and
incorporating tet operator sequences immediately downstream
from promoters directing the expression of the late A7L or D6R
genes (Fig. 1). Late VACV promoter sequences consist of an A/T-rich
stretch of approximately 20 bp, a 6 bp spacer region, and a highly
conserved TAAAT(A/G) transcriptional initiator element (Davison
and Moss, 1989). The D6R gene has an upstream intergenic region of
40 bp that is expected to contain only the late promoter for the D6R
gene, since the preceding gene (D5R) also transcribes to the right
(Fig. 1B). Therefore, this natural sequence was used to engineer a
tet-responsive (inducible) promoter for the D6R gene (PD6RO2). The
tet operator (O2) sequence was inserted after the identiﬁed puta-
tive late transcriptional initiator element sequence TAAATG, which
was changed to TAAATA to ensure translation initiation only from
the downstream D6R open reading frame (Fig. 1C and Table 1).
The intergenic region upstream from the A7L gene is 53 bp and
likely contains promoters for both the A7L and the A8R gene, since
A8R is transcribed in the opposite direction (Fig. 1B). It was not pos-
sible to accurately identify and separate the sequences for these two
promoters, so the well-characterized late promoter for the F17R
gene (P11), which has been used successfully as a lac-responsive
promoter (Fuerst et al., 1989), was  used to control the transcription
of the A7L gene (Fig. 1 and Table 1). However, this entire inter-
genic region was kept in the viral genome to ensure transcription
of the A8R gene, and the putative transcriptional initiator element
C.J. Hagen et al. / Virus Research 181 (2014) 43–52 47
Fig. 2. VACVs inducibly expressing D6R or A7L form plaques only in the presence of DOX. BS-C-1 cell monolayers were infected with the indicated VACVs at approximately
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henotypes. (B) Representative brightﬁeld microscopy images of stained cells show
re  representative of two separate experiments.
equence of the natural A7L promoter (Table 1) was  changed from
AAATA to TAAGGA to prevent transcription initiation from that
ite. The resulting recombinant VACVs (viD6R for VACV inducible
6R and viA7L for VACV inducible A7L) were expected to replicate
nly in the presence of tetracyclines.
.2. Construction of recombinant viruses
A series of cloning steps were used to build the transfer vectors
ased on existing plasmids, designed synthetic DNA sequences, and
CR cloning. The ﬁnal transfer vectors contained: (1) the selectable
. coli gpt gene and the screening marker EGFP gene as a fusion gene
gpt-EGFP) under control of a synthetic strong early/late VACV pro-
oter PE/L (Chakrabarti et al., 1997); (2) the repressor gene tetR
nder another (back-to-back) PE/L promoter; (3) a tet-responsive
romoter (PD6RO2 or P11O2) to control the expression of the target
ene (D6R or A7L, respectively); and (4) left and right recombi-
ation sequences (the ﬁrst 600 bp to the left and to the right of
he insertion points shown in Fig. 1B) to direct the precise inser-
ion of the genetic elements contained in each cassette (Fig. 1C
nd D) by homologous recombination. The recombinant viruses
iD6R and viA7L were successfully constructed and plaque puri-
ed in the presence of DOX. High-titer stocks did not develop
GFP-negative plaques that would represent unstable recombinant
ACVs or residual parental (wild-type) virus (data not shown). In
ddition, PCR analysis of viral DNA puriﬁed from high-titer stocks
ith multiple primers spanning the regions of interest (Fig. 1B and
 and Table 2) conﬁrmed the overall genetic organization of these
egions in each recombinant VACV (data not shown).
.3. viD6R and viA7L form plaques only in the presence of DOX
The ability of viD6R and viA7L to replicate in the absence or
resence of inducer was ﬁrst investigated by performing standard
laque assays in BS-C-1 cells, either in the absence or presence of
OX (1 g/ml), followed by crystal violet staining 2, 7, or 14 DPI.
solated plaques formed 2 DPI in the presence of DOX were typical
Fig. 2, top row) and identical to the wild-type WR  plaques formed
n the absence of DOX (Fig. 2, middle row). However, no plaques
ould be detected 2 DPI for viD6R and viA7L in the absence of DOX
Fig. 2, middle row). Moreover, plaques were not observed in viD6R
nd viA7L wells even 7 (data not shown) or 14 DPI, when the entire
ell infected with WR displayed cytopathic effects (Fig. 2, bottom
ow). Small foci of darker stained cells could be observed 14 DPIcrystal violet 2 or 14 DPI. (A) Image of representative wells showing the plaque
laques, when present. WR refers to VACV WR clone 9.2.4.8 (parental strain). Data
(Fig. 2, bottom row), but they were likely due to the overgrowth of
the cell monolayer as they were also present in uninfected control
wells (not shown).
3.4. viD6R and viA7L produce abortive infections in the absence
of DOX
Plaque formation in BS-C-1 cells by viD6R and viA7L was
also investigated in unﬁxed cells by brightﬁeld and ﬂuorescence
microscopy. Under ﬂuorescence microscopy, only single EGFP-
positive cells could be detected in the absence of DOX  (Fig. 3A).
Under high magniﬁcation, these cells were typical and there was
no evidence of EGFP expression in the neighboring cells (Fig. 3B).
The frequency of these cells corresponded roughly to the number
of plaques obtained in the presence of DOX, where EGFP-positive
plaques were observed (Fig. 3C). Taken together, the observations
are indicative of abortive infections. In addition, detection of high
levels of EGFP expression in these abortively infected cells suggests
that late gene expression from the PE/L promoter was not com-
promised in the absence of DOX. When DOX was  added to these
abortively infected cells 2, 4, or 6 DPI, replication was allowed to
resume and plaques were visible 2 days later (Fig. 3D shows results
for addition of DOX 48 h post-infection), indicating that transcrip-
tion of the D6R or A7L genes was sufﬁcient to allow the resumption
and completion of the replication cycle. However, plaques were not
detected when DOX was  added 8 or 10 DPI (not shown).
3.5. Transient complementation allows replication of viD6R and
viA7L in the absence of DOX
To conﬁrm that replication of viD6R and viA7L was  dependent
on the expression of the D6R or A7L genes, respectively, a transient
complementation assay was  performed in the absence of DOX. BS-
C-1 cells were infected with viD6R or viA7L and transfected with
plasmids expressing the D6R or A7L genes constitutively under the
VACV P11 promoter (pP11-D6R or pP11-A7L). Only single abortively
infected cells could be observed 2 DPI in viD6R- or viA7L-infected
wells without plasmids (Fig. 4A and B, left panels). Wells infected
with viD6R and transfected with pP11-A7L also displayed similar
numbers of abortively infected cells (Fig. 4A, right panels). How-
ever, when transfected with pP11-D6R, plaques could be detected
(Fig. 4A, middle panels). Similarly, plaques were formed in wells
infected with viA7L only when transfected with the plasmid con-
stitutively expressing the A7L gene (Fig. 4B, right panels).
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Fig. 3. VACVs inducibly expressing D6R or A7L produce abortive infections in the absence of DOX. BS-C-1 cell monolayers were infected with the indicated VACVs at
50  PFU/well in the absence or presence of DOX (1 g/ml) and cells were imaged by brightﬁeld (phase) or ﬂuorescence microscopy. In the absence of DOX only single EGFP-
positive cells were observed 2 DPI (A), and under higher magniﬁcation, EGFP expression was contained to single cells and was the only indication of infection, suggesting
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epresentative of two  separate experiments.
Complementation was also assessed by measuring virus yield
n the absence or presence of the complementing plasmids. Cells
nfected with viD6R in the absence of DOX and transfected with
P11-D6R yielded a four-log increase in virus titers when compared
o cells transfected with the non-complementing plasmid (pP11-
7L) or with no plasmid, although the yield was  not as high as
hat obtained with viD6R grown in the presence of DOX (Fig. 4C). A
imilar ﬁnding was observed with cells infected with viA7L in the
resence of the complementing plasmid pP11-A7L (Fig. 4D).
.6. viD6R and viA7L plaque sizes are indistinguishable from
ild-type (WR) VACV in the presence of different tetracyclines
The size of the plaques formed by WR,  viD6R, and viA7L in the
bsence or presence of multiple concentrations of three different
etracyclines was analyzed by plaque assay in BS-C-1 cells. The
adius of plaques formed by WR  in the presence of the three tetra-
yclines was not affected by the type or dose of tetracycline tested
Fig. 5). In the presence of 0.1 ng/ml of DOX, viD6R formed small
laques, while no plaques were observed with viA7L. At 1 ng/ml ofction (D), plaques were visible 2 days later (2 DPI in C and 4 DPI in D). Data are
DOX, both inducible viruses formed plaques that were signiﬁcantly
smaller than WR plaques. However, the size of plaques formed at
≥10 ng/ml of DOX were indistinguishable from plaques formed by
WR. In the presence of TET, plaques were formed only at ≥10 ng/ml,
and at 100 ng/ml there was  a small but statistically signiﬁcant dif-
ference between viD6R and WR plaques, but not between viA7L
and WR plaques. This shows that the system is less inducible with
TET, which is in agreement with the fact that TetR binds TET less
strongly than DOX (Degenkolb et al., 1991). In the presence of ATC,
a tetracycline derivative that exhibits minimal antibiotic activity,
plaque sizes at each concentration tested were similar to DOX,
despite the fact that ATC binds TetR about 5-fold more strongly
than DOX (Degenkolb et al., 1991). At 10 ng/ml of ATC, there was a
small but statistically signiﬁcant difference between viD6R plaques
and WR plaques, and at 0.1 ng/ml of ATC, many abortive infec-
tions were observed (data not shown) and the plaques that formed
were smaller than those formed at 0.1 ng/ml of DOX, indicating
that DOX was  a better inducer in this system. In brief, no plaques
were observed in the absence of tetracyclines and plaque forma-
tion occurred in as little as 0.1 ng/ml (viD6R) or 1 ng/ml (viA7L) of
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Fig. 4. Transient complementation allows replication of VACVs inducibly expressing D6R or A7L in the absence of DOX. BS-C-1 cell monolayers were infected with viD6R
(A  and C) or viA7L (B and D) at 100 PFU/well (A and B) or an MOI  of 0.01 (C and D) in the absence of DOX and transfected with plasmids expressing the D6R (pP11-D6R) or
A7L  (pP11-A7L) genes under the constitutive VACV P11 promoter. Plaque formation was checked 2 DPI by brightﬁeld (phase) and ﬂuorescence imaging (A and B). Virus yield
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he  data shown represent the mean viral yields from triplicate samples assayed in d
xperiments.
OX. Most importantly, viD6R and viA7L plaque sizes were indis-
inguishable from WR  at ≥10 ng/ml of DOX.
.7. viD6R and viA7L replicate indistinguishably from wild-type
WR) VACV in the presence of DOX
The kinetics of viral replication in vitro were determined in
S-C-1 cells infected with the VACVs at a low MOI  (0.01) in the
bsence or presence of DOX (1 g/ml). As expected, the wild-type
R strain replicated equally in the absence or presence of DOX
Fig. 6). Additionally, viD6R and viA7L replicated indistinguishably
rom WR  in the presence of DOX. In the absence of DOX, virus yield
y viA7L was below the input level at all time points. However,
iD6R yield was very small but detectable (close to the input level
t 0 h post-infection), despite the fact that only abortive infections
ere detected (Figs. 3 and 4). This suggests that a few mature intra-
ellular viral particles were formed in the absence of tetracyclines
ith viD6R, but not viA7L.
. Discussion
VACV is a promising vector for the development of recombinant
accines for humans and animals, as well as cancer immunothera-
ies and oncolytic therapies (Verardi et al., 2012). VACV was  used
s a vaccine for the eradication of smallpox and a recombinant
ACV vaccine that expresses the rabies virus glycoprotein (V-RG)
as been used successfully as an oral vaccine to control sylvatic
abies in Europe and North America (Pastoret and Brochier,
996). Additionally, multiple clinical trials for animal and human
accines, immunotherapies, and oncolytic therapies based on
eplication-competent VACV vectors are underway (Verardi et al.,
012). Nonetheless, safety is always a concern due to potentialand D), with input referring to initial titer determined immediately after infection.
ate. Error bars indicate standard deviation. Data are representative of two  separate
serious adverse events that can result from uncontrolled VACV
replication. While replication-defective VACVs such as MVA  and
NYVAC address safety issues, they are not as immunogenic as their
replication-competent counterparts and unsuitable as oncolytic
vectors. We  therefore used elements of the tet operon to develop
replication-inducible VACV vectors that replicate to wild-type
levels only in the presence of tetracycline antibiotics, thus allowing
control over VACV replication.
As an initial step toward the development of these replication-
inducible vectors, recombinant VACVs were designed to control the
expression of the genes encoding the two subunits of VETF, the early
transcription factor required for virus replication. In viD6R, the O2
operator sequence was  placed immediately downstream from the
transcriptional initiator element of the D6R promoter (Fig. 1 and
Table 1). In viA7L, a late P11 promoter with an O2 operator sequence
was used to control A7L gene expression, thus preserving native
expression of the A8R gene from its putative promoter (Fig. 1). In
addition, the tetR gene was constitutively expressed in both viruses
using a strong synthetic early/late VACV promoter (PE/L) (Fig. 1). We
showed that viD6R and viA7L do not form plaques in the absence
of DOX, even when cells were incubated for 2 weeks after infection
(Fig. 2). Singly infected cells could be detected by expression of the
EGFP reporter gene (Fig. 3A and B) 2 DPI, but were less evident
or not detectable 4 DPI. The neighboring cells did not show any
evidence of infection such as cytopathic effects or EGFP expression
(Fig. 3B). High levels of EGFP expression in these abortively infected
cells suggest that gene expression from the PE/L promoter was  not
compromised in the absence of DOX, in agreement with previous
ﬁndings that newly synthetized VETF is not required for early or
late gene expression (Hu et al., 1996, 1998). However, plaques were
formed in the presence of DOX (Figs. 2 and 3C) even when DOX was
added 2 (Fig. 3D), 4, or 6 DPI, indicating that the virus growth cycle
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Fig. 5. Effect of tetracyclines on the plaque sizes of VACVs inducibly expressing
D6R or A7L. BS-C-1 cell monolayers were infected with the VACVs at 30 PFU/well
in  the absence or presence of multiple concentrations of DOX (A), TET (B), or
ATC (C). At 36 h post-infection cells were stained with crystal violet and the size
(radius) of approximately 20 representative plaques was measured. Error bars indi-
cate standard deviation. Arrows indicate absence of plaques. The symbol * indicates
statistically signiﬁcant differences (P ≤ 0.05, two-way ANOVA followed by Tukey’s
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Fig. 6. VACVs inducibly expressing D6R or A7L replicate indistinguishably from
wild-type (WR) VACV in the presence of DOX. BS-C-1 cells were infected with the
indicated VACVs at a low MOI  (0.01) in the absence or presence of DOX (1 g/ml) and
where in the absence of inducer (IPTG) no plaques formed but theultiple comparisons test) when comparing WR vs. viD6R or viA7L at a given tetra-
ycline concentration. Data are representative of two separate experiments.
esumed once VETF expression was allowed. This is in agreement
ith a likely role of VETF in virion morphogenesis (Hu et al., 1996,
998). Replication did not resume when DOX was added 8 or 10 DPI
not shown), possibly because the abortively infected cells or the
irus life cycle were compromised this late after infection. In that
egard, EGFP expression in abortively infected cells faded ratherat  multiple time points the intracellular viral fractions were collected and titered on
BS-C-1 cells in the presence of DOX. The data shown represent the mean viral yields
from triplicate samples assayed in duplicate. Error bars indicate standard deviation.
quickly between 2 and 4 DPI (not shown), indicating that expression
of VACV genes was not sustained after 2 DPI.
Transient complementation assays conﬁrmed that in the
absence of DOX, viD6R and viA7L plaque formation and repli-
cation was dependent on expression of the D6R or A7L genes,
respectively (Fig. 4). In addition, plaque formation was induced by
different tetracyclines, including DOX, TET, and ATC, with DOX  and
ATC allowing plaque formation at lower concentrations (Fig. 5).
Plaques were observed in as little as 0.1 ng/ml of DOX for viD6R
and 1 ng/ml of DOX for viA7L, and at ≥10 ng/ml of DOX, the size
of plaques formed by viD6R and viA7L were indistinguishable from
plaques formed by the wild-type (WR) VACV. Most importantly, the
replication-inducible viruses replicated in cell culture to the same
levels as the parental wild-type WR VACV in the presence of DOX
(Fig. 6).
The function of the D6R gene has been studied with
temperature-sensitive mutants (Li et al., 1994). In addition,
inducible D6R and A7L viruses have been generated using lac
operon elements in a system where the bacteriophage T7 RNA
polymerase is expressed under a P11 promoter controlled by a lac
operator element, and the D6R or A7L genes are placed under T7
promoters also controlled by a lac operator element (Hu et al., 1996,
1998; Yang and Moss, 2009). In this system, addition of isopropyl-
-d-thiogalactoside (IPTG) leads to T7 RNA polymerase expression
and D6R or A7L transcription. Using this system, viruses inducibly
expressing D6R or A7L were shown to replicate only in the pres-
ence of IPTG, although about 10-fold less efﬁciently than wild-type
(WR virus) (Hu et al., 1996, 1998). In addition, small plaques could
be detected with prolonged incubation (Hu et al., 1996), likely
indicating some level of leaky expression of the inducible gene.
Interestingly, viD6R was  unable to produce plaques in the absence
of DOX, but the virus titer of viD6R in the absence of DOX increased
slightly at 12 and 24 h post-infection. However, yield was neg-
ligible when compared to viD6R grown in the presence of DOX
(Fig. 6), making viD6R an excellent replication-inducible vector.
These results are similar to those generated using the lac operon/T7
RNA polymerase system to control the expression of the D6R gene,virus titer increased slightly (Hu et al., 1996).
Replication-inducible VACVs based on the inducible expres-
sion of the D6R or A7L genes with tetracycline antibiotics
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ave the potential to be used for the development of safer
ecombinant vaccines and therapeutics. Future development
ould require the choice of an appropriate strain of VACV (such
s ACAM2000) and the generation of recombinant viruses with-
ut screening and selectable markers (e.g., by transient dominant
election) (Falkner and Moss, 1990; Papin et al., 2011). One example
ould be next-generation smallpox vaccines for non-emergency
accination of military personnel and ﬁrst-responders. One of
he problems of the current licensed smallpox vaccines is that
ACV can inadvertently be transferred to contacts. One such case
ccurred in 2007 when a child developed a life-threatening case
f eczema vaccinatum through contact with a military smallpox
accinee (Centers for Disease Control and Prevention, 2007). If a
eplication-inducible version of the vaccine had been used, inadver-
ent inoculation of contacts would have been avoided altogether as
he virus would be unable to replicate in individuals not undergo-
ng tetracycline antibiotic therapy. Another problem is that despite
edical screening prior to vaccination, complications can result
rom unforeseen or unanticipated contraindications, such as the
ase of an apparently healthy military smallpox vaccinee that
eveloped progressive vaccinia due to chemotherapy to control a
ancer diagnosed only after vaccination (Lederman et al., 2012). If a
eplication-inducible version of the vaccine had been used, the sim-
le withdrawal from tetracycline antibiotic treatment would likely
ave led to the clearance of VACV. Finally, replication-inducible
ACVs would serve as safer oncolytic vectors, since oncolytic ther-
py could be tightly controlled by administration and withdrawal
f antibiotics.
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